Longevity biotech company NewLimit has closed a $435 million Series C round, lifting its valuation to $3.1 billion and accelerating its timeline for human trials of anti-aging therapies.
The round was led by Founders Fund, with participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, Valor Equity Partners, Thrive Capital, Greenoaks, and Quiet Capital. The new capital brings NewLimit’s total disclosed funding to more than $700 million.
First human trial targeted for next year
NewLimit plans to use the fresh funding to move its first drug candidate into the clinic ahead of schedule. The company said it aims to begin a first-in-human study next year for a therapy targeting alcohol-associated liver disease.
Management described that program as a strategic entry point, arguing that liver disorders mirror many biological processes linked to accelerated aging. The goal is to win approval for a disease-specific therapy first, then broaden the use of its underlying rejuvenation technology.
NewLimit focuses on epigenetic reprogramming
Founded in 2021 in the San Francisco Bay Area by Armstrong, Byers, and Kimmel, NewLimit is building therapies that attempt to “reprogram” the biological age of cells rather than simply treating symptoms of aging.
Its approach builds on the 2006 work of Japanese scientist Shinya Yamanaka, who identified a small set of transcription factors that can revert adult cells to an embryonic-like state. These “Yamanaka Factors” earned Yamanaka the 2012 Nobel Prize in Physiology or Medicine and laid the scientific foundation for efforts to reverse cellular aging.
NewLimit says its experimental drugs aim to reset the epigenome of aging cells, restoring more youthful function. The company notes that different cell types likely require distinct combinations of transcription factors, and identifying these effective gene payloads remains the core of its research program.
Funding trajectory and rising valuation
The latest round caps a rapid funding and valuation climb for the three-year-old company. NewLimit raised $40 million in Series A funding in 2023, followed by $130 million in Series B a year later and a $45 million extension round in late 2025.
During those earlier raises, the company’s valuation rose from $810 million to $1.62 billion. The new Series C more than doubles that level, pushing NewLimit to a $3.1 billion valuation and giving it a war chest to advance multiple programs into clinical development.
Longevity biotech field attracts tech billionaires
NewLimit’s raise comes amid a broader wave of capital into longevity biotech, a niche drawing heavy interest from technology billionaires and their funds.
Sam Altman committed $180 million to Retro Biosciences, which has reached an approximate $1.8 billion valuation. Altos Labs, backed by Jeff Bezos, launched in 2022 with $3 billion and has since nearly doubled its total fundraising to close to $6 billion, securing more than $5.5 billion in available capital by late 2025.
Across these efforts, prominent technology leaders including Peter Thiel, Altman, and Bezos are directing large sums toward extending healthy lifespan and delaying age-related decline, as they pivot from traditional technology bets to advanced biotechnology.
Market outlook for longevity biotech
The longevity biotechnology market is projected to expand from $20.9 billion in 2025 to $23.2 billion in 2026, implying an 11% compound annual growth rate. In just the first quarter of 2026, companies in the space raised around $3.74 billion, a 56% increase in capital deployed compared with the same period in 2025.
This funding surge is translating into a rapid move from theoretical work to clinical-stage programs.
Industry moves toward first human data
One of the highest-profile validations of epigenetic reprogramming came in January 2026, when Life Biosciences announced that the U.S. Food and Drug Administration had accepted its application for the first human clinical trial of a cell rejuvenation therapy using this approach. Initial readouts from that trial are expected as early as the end of this year, and could serve as an important proof point for the entire field.
Separately, the Altman-backed Retro Biosciences has been advancing multiple aging-related therapies. It began a Phase 1 trial in 2025 for an autophagy-boosting drug candidate, with early human data expected around August 2026. The same company plans to start human trials this year on another program targeting microglia cells.
Altos Labs, meanwhile, pushed its own cellular reprogramming technology into human safety testing in late 2025, reinforcing its status as the sector’s best-funded player.
More flexible regulatory backdrop
These clinical milestones are unfolding under a more supportive regulatory environment. The FDA has signaled a more flexible stance toward cell and gene therapies throughout 2026, encouraging the use of accumulated scientific knowledge to streamline development.
On June 2, 2026, the agency issued new draft guidance designed to help developers leverage existing data and methodologies to simplify and speed regulatory submissions. The move is seen as a tailwind for companies like NewLimit, which aim to bring novel longevity therapies into trials faster.
Biotech rebound draws capital back to risk
The acceleration in longevity biotech is occurring alongside a broader rebound in the sector. After several years of underperformance, biotech stocks staged a sharp recovery in the second half of 2025. The SPDR S&P Biotech ETF surged about 75% from its April 2025 lows, decisively outperforming the wider equity market.
Analysts describe this as part of a broader rotation back into higher-risk growth areas, fueled by renewed mergers and acquisitions activity and a clearer regulatory and policy backdrop.
Single-list summary of key shifts
- Large new funding rounds in longevity biotech, including NewLimit’s $435 million Series C and multi-billion-dollar war chests at Altos Labs and other players
- Faster transition from lab research to human trials in epigenetic reprogramming and related therapies
- A more permissive FDA posture on cell and gene therapies, with new draft guidance aimed at accelerating development
- A strong rebound in biotech equities, highlighted by the SPDR S&P Biotech ETF’s roughly 75% rally from 2025 lows, drawing capital toward high-growth health and longevity themes
Capital rotation and implications for other assets
The renewed focus on biotech has implications beyond healthcare. Market analysts note that concentrated gains in a single equity sector can form a “capital black hole,” where liquidity flows into a dominant theme at the expense of other asset classes.
A previous rotation into biotech and technology stocks in 2015 coincided with nearly a 20% slide in Bitcoin’s price, as growth-focused traders redirected funds toward areas viewed as having more immediate, transformational potential.
With NewLimit’s latest round adding momentum to the longevity trade, attention is now on how sustained interest in high-growth biotech may again influence capital allocation across equities, digital assets, and other risk markets.
Want to understand how traditional and crypto finance intersect as tech billionaires back longevity? Explore our guide to TradFi vs DeFi.
Disclaimer: The content on this page is provided for general informational purposes only and does not represent the views or financial advice of Toobit. We make no guarantees regarding the accuracy or completeness of this information and shall not be held liable for any errors, omissions, or outcomes resulting from its use. Investing in digital assets involves risk; users should independently evaluate their financial situation and the risks involved. For further details, please consult our Terms of Service and Risk Disclosure.
